Page last updated: 2024-09-04

rp 73401 and roflumilast

rp 73401 has been researched along with roflumilast in 13 studies

Compound Research Comparison

Studies
(rp 73401)
Trials
(rp 73401)
Recent Studies (post-2010)
(rp 73401)
Studies
(roflumilast)
Trials
(roflumilast)
Recent Studies (post-2010) (roflumilast)
9202356690425

Protein Interaction Comparison

ProteinTaxonomyrp 73401 (IC50)roflumilast (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)0.0008
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)0.0005
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.0003
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.025
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0475
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)0.0008
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)0.001
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)0.0008
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)0.0008

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (30.77)29.6817
2010's7 (53.85)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY1
Barlow, DJ; Ehrman, TM; Hylands, PJ1
Anzola, JV; Beauregard, C; Chen, J; Coyle, AR; Gamache, DA; Govek, SP; Hellberg, MR; Hsien, JN; Lerch, JM; Liao, JC; Malecha, JW; Noble, SA; Oshiro, G; Shiau, AK; Staszewski, LM; Thomas, DJ; Yanni, JM1
Ashton, TD; Bland, ND; Campbell, RK; Cotter, K; Fang, AP; Gangurde, R; Garceau, N; Gechijian, L; Gustafson, AE; McAllister, G; Ochiana, SO; Ondrechen, MJ; Ortenberg, R; Pollastri, MP; Tallman, C; Wang, C; Wang, Z1
de Esch, IJ; de Graaf, C; Jansen, C; Kanev, GK; Kooistra, AJ; Leurs, R1
He, J; Ke, H; Peng, T; Qi, B; Shi, J1
Dai, YR; Xia, XD; Xu, ZJ1
Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L1
Husfeld, C; Ji, YH; Klein, U; Linnevers, C; McCluskie, K; Thomas, GR; Yang, A1
Dunkern, T; Hatzelmann, A; Selige, J1
Barg, M; Geerts, A; Quednau, R; Tersteegen, A; Wunder, F1
Bailie, M; Chibucos, L; Christensen, PJ; Dils, AJ; Hazama, M; Horowitz, JC; Matsuo, T; Muraki, Y; Nikam, S; Sisson, TH; Subbotina, N; Tohyama, K1
Abou Saleh, L; Aragon, IV; Boyd, A; Koloteva, A; McDonough, W; Murphy, JM; Rich, J; Richter, W1

Reviews

2 review(s) available for rp 73401 and roflumilast

ArticleYear
Advances in the Development of Phosphodiesterase-4 Inhibitors.
    Journal of medicinal chemistry, 2020, 10-08, Volume: 63, Issue:19

    Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Development; Drug Discovery; Humans; Molecular Structure; Phosphodiesterase 4 Inhibitors; Protein Conformation; Quinolones; Vomiting

2020
[Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2004, Volume: 27, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Asthma; Benzamides; Bronchodilator Agents; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Lung Diseases; Nitriles; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridines

2004

Other Studies

11 other study(ies) available for rp 73401 and roflumilast

ArticleYear
Structural basis for the activity of drugs that inhibit phosphodiesterases.
    Structure (London, England : 1993), 2004, Volume: 12, Issue:12

    Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary

2004
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Anti-Inflammatory Agents; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Databases, Factual; Drug Design; Drugs, Chinese Herbal; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Medicine, Chinese Traditional; Models, Chemical; Models, Molecular; Molecular Conformation; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship

2010
Water-soluble PDE4 inhibitors for the treatment of dry eye.
    Bioorganic & medicinal chemistry letters, 2010, May-01, Volume: 20, Issue:9

    Topics: 4-Aminopyridine; Animals; Anti-Inflammatory Agents; Binding Sites; Computer Simulation; Coumarins; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dry Eye Syndromes; Phosphodiesterase 4 Inhibitors; Rabbits; Rats; Water

2010
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
    Journal of medicinal chemistry, 2011, Dec-08, Volume: 54, Issue:23

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Catalytic Domain; Humans; Models, Molecular; Molecular Structure; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African

2011
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
    Journal of medicinal chemistry, 2016, Aug-11, Volume: 59, Issue:15

    Topics: Databases, Protein; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship

2016
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bronchial Spasm; Bronchoalveolar Lavage Fluid; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Immunization; Male; Neutrophils; Nitriles; Ovalbumin; Phosphodiesterase Inhibitors; Pneumonia; Pyridines; Rats; Respiratory Hypersensitivity; Rolipram; Serotonin; Treatment Outcome; Tumor Necrosis Factor-alpha

2006
Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Humans; Inflammation; Interleukin-8; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Phosphodiesterase Inhibitors; Pyridines

2006
The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion.
    Journal of cellular physiology, 2011, Volume: 226, Issue:8

    Topics: Aminopyridines; Benzamides; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Fibroblast Growth Factor 2; Fibroblasts; Gene Expression Profiling; Humans; Interleukin-1beta; Isoenzymes; Lung; Myofibroblasts; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Pyridines; RNA, Small Interfering; Transfection; Transforming Growth Factor beta

2011
Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines.
    Molecular pharmaceutics, 2013, Oct-07, Volume: 10, Issue:10

    Topics: Aminopyridines; Animals; Benzamides; CHO Cells; Cricetulus; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide-Gated Cation Channels; Cyclohexanecarboxylic Acids; Cyclopropanes; Humans; Models, Biological; Nitriles; Phosphodiesterase 4 Inhibitors; Pyridines; Receptors, Adrenergic, beta-1; Reverse Transcriptase Polymerase Chain Reaction

2013
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
    Physiological reports, 2018, Volume: 6, Issue:12

    Topics: Alveolar Epithelial Cells; Aminopyridines; Animals; Benzamides; Cells, Cultured; Chemokines; Cyclic AMP; Cyclopropanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibroblasts; Humans; Isoquinolines; Mice, Inbred C57BL; Mice, Transgenic; Phosphodiesterase 4 Inhibitors; Pulmonary Fibrosis; Pulmonary Surfactant-Associated Protein D; Pyridines; Tumor Necrosis Factor-alpha

2018
PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020, Volume: 34, Issue:9

    Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Female; Gastroparesis; Mice; Mice, Nude; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidinones; Rolipram

2020